Skip to content

To evaluate the clinical efficacy of dietary supplement "Pi-vit" in the treatment of physiological floaters in Chinese

To evaluate the clinical efficacy of dietary supplement "Pi-vit" in the treatment of physiological floaters in Chinese

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086555
Enrollment
Unknown
Registered
2024-07-05
Start date
2023-09-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitreous opacity

Interventions

Mild myopia group:The subjects were given 1 tablet of Pi-Vit orally once a day after enrollment
Moderate myopia group:The subjects were given 1 tablet of Pi-Vit orally once a day after enrollment
High myopia group:The subjects were given 1 tablet of Pi-Vit orally once a day after enrollment

Sponsors

Hangzhou Xihu Eye Hospital at Zhijiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, initial onset of disease duration =1 day, =6 months, patients reported obvious floaters symptoms, no obvious retinopathy 2. B-ultrasound examination revealed a significant vitreous opacity, consistent with a physiological floater diagnosis 3. Clear refractive stroma with the exception of the vitreous, no corneal and lens opacity 4. Positive treatment attitude, understanding of the purpose of the trial, voluntary participation and signing of informed consent, and ability to complete all experimental follow-up

Exclusion criteria

Exclusion criteria: 1. Pathological vitreous opacity, including vitreous hemorrhage, stellate vitreous degeneration, intraocular malignant tumors, uveitis, retinal detachment, etc. 2. Accompanied by obvious flashy sense; 3. Peripheral vitreoretinal traction or macular vitreous traction; 4. Appear with retinopathy, such as peripheral degeneration, retinal stage; 5. People with diabetes; 6. The history of intraocular drug injection; 7. History of vitreoretinal surgery; 8. History of intraocular laser therapy; 9. The history of ocular trauma; 10. The history of gastrointestinal disease; 11. History of drugs and food allergies; 12. Moderately severe depression, anxiety and other mental illnesses; 13. Don't insist on the visitor.

Design outcomes

Primary

MeasureTime frame
The degree of vitreous opacity was quantified by B-ultrasound;Score of floaters symptoms;Visual quality rating scale;Psychological anxiety score;

Secondary

MeasureTime frame
Uncorrected visual acuity;Intraocular pressure;Fundus panoramic color photography;optical coherence tomography(OCT);

Countries

China

Contacts

Public ContactLili Chen

Hangzhou Xihu Eye Hospital at Zhijiang

cll921028@163.com+86 137 3809 7981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026